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Disulfiram/copper selectively eradicates AML leukemia
stem cells in vitro and in vivo by simultaneous induction
of ROS-JNK and inhibition of NF-κB and Nrf2
Bing Xu*,1,2,4, Shiyun Wang2,4, Rongwei Li2,4, Kai Chen2, Lingli He2, Manman Deng1, Vinodh Kannappan3, Jie Zha1, Huijuan Dong2 and
Weiguang Wang3
Acute myeloid leukemia (AML) is a heterogeneous malignancy. Despite the advances in past decades, the clinical outcomes of
AML patients remain poor. Leukemia stem cells (LSCs) is the major cause of the recurrence of AML even after aggressive treatment
making, promoting development of LSC-targeted agents is an urgent clinical need. Although the antitumor activity of disulfiram
(DS), an approved anti-alcoholism drug, has been demonstrated in multiple types of tumors including hematological malignancies
such as AML, it remains unknown whether this agent would also be able to target cancer stem cells like LSCs. Here, we report the
in vitro and in vivo activity of DS in combination with copper (Cu) against CD34+/CD38+ leukemia stem-like cells sorted from KG1α
and Kasumi-1 AML cell lines, as well as primary CD34+ AML samples. DS plus Cu (DS/Cu) displayed marked inhibition of
proliferation, induction of apoptosis, and suppression of colony formation in cultured AML cells while sparing the normal
counterparts. DS/Cu also significantly inhibited the growth of human CD34+/CD38+ leukemic cell-derived xenografts in NOD/SCID
mice. Mechanistically, DS/Cu-induced cytotoxicity was closely associated with activation of the stress-related ROS-JNK pathway
as well as simultaneous inactivation of the pro-survival Nrf2 and nuclear factor-κB pathways. In summary, our findings indicate
that DS/Cu selectively targets leukemia stem-like cells both in vitro and in vivo, thus suggesting a promising LSC-targeted activity
of this repurposed agent for treatment of relapsed and refractory AML.
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It is widely accepted that acute myeloid leukemia (AML), a
clinically and biologically clonal disorder of hematopoietic
progenitor cells, is initiated from a small subset of leukemia
stem cells (LSCs).1,2 LSCs are relatively quiescent and thus
highly resistant to chemotherapy and radiotherapy, therefore
primarily contributing to the dismal clinical outcome for AML.3,4
Despite the conventional multi-drug combinational therapies,
the most preferred and efficacious treatment, have largely
improved the long-term disease-free survival (DFS) of patients
with AML, virtually all of these patients will however eventually
relapse owing to drug-resistant LSCs that are not eradicated
by current standard therapies. Thus, this has become a major
hindrance to success of AML treatment.5 To prolong the
duration of DFS as well as overall survival, new therapeutic
agents targeting LSCs with low/non systemic toxicity are
urgently needed for AML treatment.
LSCs are well accepted to be a CD34-positive and
CD38-negative cell population with the ability to reconstitute
human AML in immunodeficient mice regardless of the
morphological subtype of AML,6 although recent studies have
suggested that LSCs could also exist in CD34+/CD38+ or
CD34− blast populations at least in some types of AML.7 KG1α
and Kasumi-1 cell lines derived from male AML patients, both
of which have high percentage of CD34+CD38− population,
are widely used for in vitro and in vivo studies of LSCs.8
Disulfiram (DS) is a Food and Drug Administration
(FDA)-approved anti-alcoholism drug that has been used in
clinic for 460 years.9,10 As a divalent metal ion chelator, DS
is able to strongly chelate copper (Cu) to form a disulfiram/
copper (DS/Cu) complex that has been reported to be highly
active against various types of tumors, including
melanoma,11–13 breast cancer,14–16 colon cancer,17 prostate
cancer,18 as well as hematological malignancies including
myeloid leukemia,19,20 but display low toxicity. However, it
remains unknown whether DS/Cu would also be capable to
target cancer stem cells such as LSCs.
Reactive oxygen species (ROS), the product of mitochon-
dria oxidative phosphorylation, has a crucial role as an
intracellular messenger in numerous biological events, includ-
ing cell proliferation and survival. It is a consensus that
excessive production of ROS results in peroxidation of lipid,
protein, and DNA, leading to cellular damage and apoptosis.21
As tumor cells usually have to deal with higher levels of ROS
than their normal counterparts, further increase of ROS by
ROS-inducing agents, such as DS/Cu, could exhaust the
cellular antioxidants, therefore resulting in apoptosis of tumor
cells.19,22 C-jun NH2-terminal kinase (JNK), an important
member of the MAPK family, has a crucial role in a variety of
stress-triggered responses, including differentiation and
apoptosis.23,24 Furthermore, it has also been demonstrated
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that ROS-mediated apoptosis is closely associated with
persistent activation of the JNK pathway.25,26
Nuclear factor-κB (NF-κB), a transcription factor usually
activated by inflammatory stimuli and cellular stresses, has a
pivotal role in regulation of cell survival and growth.27 NF-κB
has also been found to be essential for survival of cancer stem
cells including LSCs, whereas inhibition of NF-κB triggers
apoptosis of these cells.27 NF-E2-related factor-2 (Nrf2) is a
transcription factor that mediates cytoprotective antioxidant
responses and thus prevents cells from the damage induced
by ROS and other harmful chemicals in various types of
cancers.28 In addition to its tumorigenic function through
stress responses, activation of Nrf2 is also associated with
drug resistance to standard chemotherapy aswell aswith poor
survival of cancer patients.29–31 Therefore, a possibility arises
whether simultaneous inhibition of NF-κB and Nrf2 might lead
to increased efficacy of an antitumor agent, thereby represent-
ing an attractive and promising avenue to success of cancer
treatment, particularly due to targeting these two signals
crucial for survival of cancer stem cells like LSCs.
Here, we report that DS in combination with Cu has a potent
and selective anti-leukemia property in vitro against leukemia
stem-like cells (e.g., CD34+/CD38− KG1α and Kasumi-1 cells
and primary CD34+ cells isolated from AML patients) as well
as is highly effective in vivo in CD34+/CD38− leukemic
cell-derived xenograft mouse models, in association with
induction of apoptosis via activation of the stress-related
ROS-JNK pathway and inhibition of the pro-survival Nrf2 and
NF-κB pathways.
Results
Enrichment of leukemia stem-like cells from the human
AML KG1α cell line. Leukemia stem-like cells were enriched
from KG1α cell line, a subclone cell line of KG1 cells, by
sorting a CD34+/CD38− cell population using fluorescence-
activated cell sorting (FACS). As shown in Figure 1a,
percentage of the CD34+/CD38− population was significantly
increased after sorted from KG1α cells (93.2±2.7% versus
59.4±6.2% for KG1α cells before sorting; Figure 1a, right
panel; t=−8.675, P=0.001). As KG1a cells might have lost
myeloid features (e.g., the pan-myeloid antigen MY9),32 we
further performed flow cytometry to monitor the markers of
myeloid cells. As shown in Figure 1b, these CD34+/CD38−
leukemia stem-like cells displayed positivity of the myeloid
markers CD13 (99.1%), CD33 (98.6%), and CD123 (93.7%),
suggesting that certain myeloid features remain in these
sorted CD34+/CD38− KG1α cells.
DS/Cu is cytotoxic against leukemia stem-like cells
in vitro in a dose-dependent manner. First, we examined
the cytotoxic effect of DS/Cu on CD34+/CD38− leukemia
stem-like cells sorted from KG1α cells by MTT assay. As
shown in Figure 2a, after exposure to a series of the indicated
concentrations of DS with or without Cu (1 μM) for 24 h,
inhibition of CD34+/CD38− cell proliferation was significantly
increased in a dose-dependent manner, with IC50 value of
0.54±0.18 μM for DS. Furthermore, this event was
markedly enhanced by co-treatment with Cu, with a reduction
of IC50 values to 0.21± 0.03 μM (DS/Cu versus DS, t=3.107,
P= 0.036), whereas treatment with Cu alone had no
significant effect on cell proliferation (inhibition rate=0.66±
3.36%, P= 0.748 versus untreated control). Analogous
results were obtained in leukemia stem-like cells sorted from
Kasumi-1 cells, another human AML cell line, with
92.7±3.1% of CD34+/CD38− cells (Supplementary
Figure 1A). As shown in Supplementary Figure 1B, the
inhibitory effect on cell proliferation was significantly
increased after exposed to DS in combination with Cu in a
dose-dependent manner, compared with DS
administrated alone.
To further confirm the cytotoxicity of DS/Cu, CD34+/CD38−
KG1α cells were treated with DS at different concentrations
(0.05, 0.5, 5 μM) in the presence or absence of 1 μM Cu for
24 h, and then subjected to flow cytometric analysis after
Annexin V/PI double staining. Administration of Cu alone
failed to induce apoptosis, compared with untreated control
(5.6± 4.0% versus 4.75±2.6%, t= 0.474,P=0.66). However,
co-exposure to different concentrations of DS and Cu resulted
in significantly increased apoptosis in CD34+/CD38− cells
(Figures 2b and c; Po0.01 versus DS alone for each dose of
DS). Similarly, in CD34+/CD38− Kasumi-1 cells, DS in
combination with Cu (1 μM) also displayed a remarkably
increased property of apoptosis induction in a dose-
dependently manner, whereas treatment with DS alone was
barely able to trigger apoptosis (Supplementary Figure 1C;
DS/Cu versus DS alone, Po0.05 for each dose of DS).
We then examined whether DS/Cu would affect clonogeni-
city of leukemia stem-like cells, by the colony-forming assay.
As shown in Figures 2d and e, whereas treatment with Cu
(1 μM) alone had no effect on colony formation (P=0.77
versus untreated control), exposure to DS alone moderately
inhibited colony formation was (mean colony-forming units
(CFU) inhibition rate, 69.29±19.54% for 0.1 μM DS, Po0.05
versus untreated control), which was sharply enhanced when
DS and Cu were administrated together in CD34+CD38−
KG1α cells (48.55±14.36% for 0.01 μM DS, Po0.05 and
Po0.01 versus untreated control and DS alone, respectively;
0.83±0.72% for 0.1 μM DS, Po0.001 and Po0.01 versus
untreated control and DS alone, respectively). Taken together,
these results suggest that whereas DS itself displays notice-
able dose-dependent cytotoxicity toward leukemia stem-like
cells, while this effect is markedly potentiated when combined
DS with non-toxic concentrations of Cu.
DS/Cu-mediated cytotoxicity is dependent upon intracel-
lular ROS production in leukemia stem-like cells. Pre-
vious studies have indicated that generation of intracellular
ROS is crucial for induction of apoptosis by chemotherapeutic
agents in various types of cancers.33 To determine whether
DS/Cu-induced apoptosis would rely on intracellular ROS
production, we thus measured the ROS level in CD34+CD38−
KG1α cells after exposed to DS/Cu for 6, 12, 18, 24 h, using
the DCFH-DA-based assay. As shown in Figures 3a and b,
co-administration of DS (0.5 μM) and Cu (1 μM) resulted in a
robust increase in intracellular ROS accumulation at different
time points (Po0.001 for each interval except 6 h, compared
with untreated control and DS alone, respectively), in
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association with induction of apoptosis by DS/Cu (Figures
2b and c).
We next investigated the functional role of ROS in induction
of apoptosis by DS/Cu in leukemia stem-like cells, by
employing the free radical scavenger N-acetyl-cysteine
(NAC). Apoptosis was analyzed after co-exposed to different
concentrations of DS and Cu (1 μM) in the presence or
absence of NAC (10 mM) for 24 h in both CD34+/CD38− KG1α
and Kasumi-1 cells, respectively. As shown in Figure 3c,
treatment with NAC clearly abrogated apoptosis induced by
DS/Cu in CD34+/CD38− KG1α cells (Po0.05 versus DS/Cu
for each dose of DS), whereas NAC itself had almost no effect
on apoptosis (P=0.762 versus untreated control). Moreover,
identical treatment with NAC also partly rescued CD34+
/CD38− Kasumi-1 cells from apoptosis induced by DS/Cu as
shown in Supplementary Figures1E and 1F (Po0.05 for each
group, DS/Cu/NAC versus DS/Cu).
The similar results were also obtained in primary CD34+
cells isolated from bone marrow samples of the AML patients
#3, #4, #5, and #11. As shown in Figures 3d–f, after exposure
to DS (0.1 μM) with or without Cu (1 μM) for 6 h, a significant
increase in intracellular ROS level was observed in primary
CD34+ AML cells (Po0.01, DS/Cu versus untreated control;
Po0.05, DS/Cu versus DS alone). Furthermore, co-
administration with NAC also remarkably abolished apoptosis
induced by DS/Cu in primary CD34+ AML cells (P=0.001 for
DS/Cu versus untreated control; P= 0.003 DS/Cu/NAC
versus DS/Cu), whereas NAC itself did not affect apoptosis
(P= 0.947 versus untreated control). Together, these results
suggest that DS/Cu-induced apoptosis in leukemia stem-like
cells is highly dependent on generation of intracellular ROS.
DS/Cu inhibits the Nrf2 and NF-κB pathways as well as
activates the JNK pathway in leukemia stem-like cells.
Given the previous observations that ROS-mediated apopto-
sis highly relies on activation of JNK, the effect of DS/Cu on
the JNK pathway was assessed in CD34+/CD38− KG1α cells.
As shown in Figure 4a, exposure to DS resulted in a clear
increase in phosphorylation of both JNK (p-JNK) and its
downstream target c-jun (p-c-jun), which was remarkably
enhanced by co-administration of Cu.
Previous reports have also demonstrated that DS inhibits
NF-κB, in association with its potent antitumor activity.34
Notably, treatment with DS alone for 24 h effectively down-
regulated the expression of p65, a core component of the
NF-κB family, accompanied by markedly reduced expression
of the NF-κB target genes survivin and c-myc, and these
events were clearly enhanced when DS was administrated
with Cu in combination (Figure 4b).
As Nrf2 has an important role in activation of antioxidant
responses to ROS,8 Nrf2 and its downstream gene expression
was monitored by western blot analysis and RT-PCR after
exposed to DS (0.5 μM) with or without Cu (1 μM) for 24 h.
Treatment with DS or DS/Cu significantly reduced the protein
level of Nrf2 in CD34+/CD38− KG1α cells (Figure 4c). Of note,
whereas DS or Cu alone displayed a modest effect (P40.05
versus untreated control), combined administration of DS/Cu
dramatically inhibited the expression of the Nrf2 downstream
genes, including HO-1, NQO1, and GSR, in CD34+/CD38−
KG1α cells (Figure 4d).
Comparable results were also observed in primary CD34+
cells isolated from bone marrow samples of the AML patient
#2 and patient #5. As shown in Figures 4f and g, ex vivo
treatment with DS/Cu resulted in a sharp decrease in the
Figure 1 Enrichment of leukemia stem-like cells from KG1α cell line. Percentage of CD34+/CD38− population was analyzed by flow cytometry before (a, left panel) and after
sorting (right panel). Before sorting, the CD34+/CD38− KG1a cells were 59.4± 6.2%. After sorting, the percentage of CD34+/CD38− is 93.2± 2.7%. (b) Myeloid surface markers
(CD13, CD33, and CD123) in sorted KG1a cells were detected by flow cytometry. The filled grey area represents isotype control staining
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protein level of p65 in both patient samples, whereas DS and/
or Cu alone or in combination also increased phosphorytions
of p-JNK (particularly p46 isoform) and p-c-jun (36 kDa, lower
band), as well as downregulated Nrf2 in these samples in
primary CD34+ AML cells.
The free radical scavenger NAC reverses the DS/Cu-
induced alterations in the Nrf2 and JNK pathways. To
examine a possibility whether the alterations of Nrf2 expres-
sion and JNK activation would be linked to ROS, NAC
(10 mM) was used to test the role of ROS in these events
induced by DS/Cu. As shown in Figure 4e, downregulation of
Nrf2 and phosphorylation of JNK induced by DS/Cu were
markedly blocked by NAC in CD34+CD38− KG1α cells,
suggesting that ROS might act upstream of the Nrf2 and JNK
pathways in leukemia stem-like cells treated with DS/Cu.
DS/Cu selectively targets primary CD34+ AML stem-like
cells while sparing normal hematopoietic progenitor
cells. To validate the activity of DS/Cu against leukemia
Figure 2 DS/Cu is cytotoxic toward leukemia stem-like cells in vitro. (a) Dose-dependent DS/Cu-induced effect on cell proliferation. (b) Histogram of apoptosis percentage in
CD34+/CD38− KG1a leukemia stem-like cells. **Po0.01. (c) Representative data for flow cytometric analysis of Annexin V/PI dual staining in CD34+/CD38− KG1a cells after
treated with indicated concentrations of DS with or without Cu (1 μM) for 24 h. (d) Dose-dependent effect on colony-forming ability after treatment with DS or DS/Cu for 18 h. (e)
Histogram of colony-forming ability in CD34+/CD38− KG1a cells. *Po0.05, **Po0.01, ***Po0.001. Data were presented as mean± S.D. for three independent experiments
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Figure 3 DS/Cu-induced cytotoxicity is associated with intracellular ROS accumulation in leukemia stem-like cells. (a) CD34+/CD38− KG1a cells were treated with DS
(0.5 μM) ± Cu (1 μM) for the indicated intervals. Intracellular ROS level was determined by analysis of DCFH-DA fluorescence intensity. (b) Histogram of ROS generation in
CD34+/CD38− KG1a. ***Po0.001. (c) Histogram of apoptosis percentage in CD34+/CD38− KG1a cells in the presence of free radical scavenger NAC (10 mM) ± DS/Cu for
24 h. *Po0.05. (d) Intracellular ROS level was examined by analysis of DCFH-DA fluorescence intensity. Primary CD34+ samples isolated from AML patient #3, #4, #5, #11 were
treated with DS (0.1 μM) +/- Cu (1 μM) for 6 h. *Po0.05, **Po0.01. (e) Histogram of ROS generation in CD34+ primary cells (n= 4). (f) Histogram of apoptosis percentage in
CD34+ primary cells (n= 4) after treated with DS/Cu or DS/Cu/NAC
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stem-like cells, CD34+ cells were isolated by magnetic
activated cell sorter (MACS) from AML patients and healthy
donors for hematopoietic stem cell transplantation, respec-
tively. Clinical characteristics of these AML patients are
summarized in Table 1. Consistent with the anti-leukemia
effect of DS/Cu observed in CD34+/CD38− KG1α cells,
treatment with 0.5 μM DS with or without 1 μM Cu-induced
apoptosis of CD34+ AML cells (Figure 5a; P= 0.012 and
Po0.001 DS and DS/Cu versus untreated control, respec-
tively; n= 14), whereas Cu alone (1 μM) was unable to induce
apoptosis (15.92± 12.1% versus 11.45±6.8% for Cu alone
versus untreated control, P=0.966). Of note, although
administration of DS alone at low doses (e.g., 0.1 μM) did
not significantly induced apoptosis (P=0.52, compared with
untreated control), combined treatment with Cu (1 μM) led to
a marked increase in apoptosis of CD34+ AML cells
(Figure 5a; P=0.009 for DS/Cu versus untreated control).
In sharp contrast, the identical treatment failed to induce
apoptosis in normal CD34+ hematopoietic cells (Figure 5b;
P40.05 for DS/Cu versus untreated control in all cases).
Three patients (#7, 8, and 12) with secondary AML (sAML)
evolved from a preceding phase of myelodysplastic syndrome
(MDS) were also enrolled in the present study. Unexpectedly,
consistent with the ex vivo activity in primary samples from
AML patients, DS/Cu also exhibited a potent antitumor activity
against CD34+ cells isolated from these three patients with
sAML (49.4± 14.5% and 67.8± 21.5% versus 10.6±8.3% for
0.5 μM DS alone and 0.5 μM DS/1 μM Cu versus untreated
control, P= 0.002 and Po0.001, respectively). Further two-
way analysis of variance (ANOVA) analysis revealed no
significant difference in the cytotoxic effect of DS/Cu between
sAML (n=3) and primary AML (n= 11; P= 0.62).
Figure 4 DS in combination with Cu suppresses expression of Nrf2 and NF-κB while activates the JNK pathway in leukemia stem-like cells. (a, b) CD34+/CD38− KG1α cells
were incubated with 0.5 μM DS ± 1 μM Cu for 24 h, flowed by western blot analysis to monitor expression of the JNK (a) and NF-κB (b) pathway-related proteins. (c) Western
blotting analysis of Nrf2 protein level in CD34+/CD38− KG1α cells after DS or DS/Cu treatment for 24 h. (d) Relative mRNA expression of downstream genes (HO-1, NQO1 and
GSR) of the Nrf2 pathway in CD34+/CD38− KG1α cells. Data were presented as mean±S.D. of three independent experiments. **Po0.01, ***Po0.001. (e) Western blot
analysis for the expression of Nrf2 and p-JNK in CD34+/CD38− KG1α cells after co-treatment with DS/Cu and NAC. (f, g) Western blot analysis for the detection of JNK, Nrf2, and
P65 pathway expression in primary CD34+ AML cells isolated from patient #2 (f) and patient #5 (g), after exposure to DS with or without Cu for 24 h
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Colony formation assay was then carried out to assess
clonogenicity of primary CD34+ AML stem-like cells and
CD34+ normal hematopoietic cells, respectively. As shown in
Figure 5c, DS alone at low doses (0.05 μM and 0.1 μM)
significantly reduced the number of CFU of primary CD34+
AML cells after cultured for 10–14 days (Po0.05 and Po0.01
for 0.05 μMand 0.1 μM versus untreated control, respectively),
whereas combined treatment with DS and Cu (1 μM)
further reduced the number of CFU (Po0.01 versus untreated
control in all cases). It is noteworthy that the identical treatment
with DS alone or DS/Cu exhibited almost no effect on the
number of CFU of normal CD34+ hematopoietic cells
(Figure 5d; P40.05 versus untreated control for each
condition). Therefore, these findings suggested that DS/Cu
might have highly effective anti-leukemia activity against
leukemia stem-like cells, with low toxicity toward normal
hematopoietic progenitor cells.
DS/Cu suppresses growth of xenograft derived from
CD34+/CD38− leukemia stem-like cells. Last, to assess
in vivo antitumor effects of DS/Cu, CD34+/CD38− KG1α cells
were grafted in mice to a leukemia mouse model as
described in detail in Methods. As shown in Figure 6a, a
significant inhibition of tumor growth was observed after
DS/Cu treatment, arguing the antitumor activity of DS/Cu
in vivo. Average body weight of mice treated with vehicle
(PBS) was 17.80± 0.41 g after 2 weeks, whereas was
18.07±0.35 g and 19.02± 0.39 g for Ara-C group and
DS/Cu group, respectively (Po0.05 for DS/Cu group versus
the group of mice received either vehicle or Ara-C, a standard
agent currently used to treat AML in clinic). In addition,
treatment with either DS/Cu and Ara-C remarkably reduced
tumor burden, manifested by a significant decrease in
percentage of blast cells in bone marrow (Figure 6b;
24.73±1.48% for DS/Cu group versus 34.96±1.94% for
vehicle group, Po0.001; 24.56± 2.25% for Ara-C group
versus 34.96±1.94% for vehicle group, Po0.001). However,
there was no statistically significant difference between
DS/Cu and Ara-C groups (P40.05). Moreover, HE staining
and immunohistochemistry for human CD45 at 6th week
following transplantation demonstrated that the ability of
blast cells to invade liver and spleen was remarkably
impaired in mice treated with DS/Cu or Ara-C, compared
with those in mice received vehicle as control
(Figure 6c). Finally, western blot analysis revealed that
treatment with DS/Cu also reduced Nrf2 protein level in
spleen cells (Figure 6d), consistent with the results observed
in vitro.
Discussion
Development of new drug is a costly and time-consuming
process. Therefore, exploring new functions for existing drugs,
termed repurposing or repositioning, has attracted great
attention owing to low cost and fast track. DS, a member of
the dithiocarbamate family and which is an aldehyde
dehydrogenase inhibitor and a Cu chelator, has been
approved by FDA for the treatment of alcoholism for more
than six decades.9,10 Cu is an essential trace element for
tumor cell proliferation and thus could serve as a selectiveTa
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target for cancer therapies.22 Despite the concept of using Cu
to tackle cancer that was proposed many decades ago,
intracellular transport of Cu remains a major hurdle for its
clinical application. However, this problem might be solved by
combination of Cu with DS, as the derivative N,N-diethyl-
dithiocarbamte (deDTC) of DS can bind to Cu to form a Cu
(deDTC)2 complex and thereby improve the intracellular
trafficking of Cu.13
Recently, the anticancer activity of DS have attracted many
attentions in various types of cancers. Here, we demonstrated
that DS, particularly when co-administrated with non-toxic
concentrations of Cu (e.g., 1 μM), was highly cytotoxic to
leukemia stem-like cells, including CD34+/CD38− KG1α cells
and CD34+/CD38− Kasumi-1, as well as primary CD34+ cells
isolated from AML patients, in a dose-dependent manner,
whereas largely sparing normal hematopoietic progenitor
cells. Compared with normal cells, AML cells might generally
have higher level of Cu, which enables DS to target AML cells
selectively. The present in vitro results indicate that in the
absence of Cu, the concentration of DS required for antitumor
action was markedly higher than that in the presence of Cu
(0.54 μM versus 0.21 μM) in CD34+CD38− KG1α cells,
suggesting the necessity of free Cu in the cytotoxic effect of
DS/Cu in combination. Of note, IC50 of DS in combination with
non-toxic Cu against leukemia stem-like cells was significantly
lower than the concentration recommended for alcoholism
treatment (500 mg asmaximum daily dosage),35 implying high
antitumor efficacy but low non-specific toxicity of DS. In
addition to the anti-proliferation function, DS/Cu also had a
marked effect on both induction of apoptosis and impairment
of clonogenicity of leukemia stem-like cells, including primary
CD34+ AML cells, with minimally toxicity towards normal
counterparts obtained from healthy donors. We also obtained
encouraging results in xenograft animal models derived from
leukemia stem-like cells, reflected by both reduction of tumor
burden as well as inhibition of blast cell invasion into vital
organs such as liver and spleen. Together, these findings
argue that DS/Cu has a promising potential to be safely used
to treat AML in clinic.
sAML is a poorly defined term that often refers to AML
developed following a previous disease, such as MDS or
chronic myeloproliferative disorder.36 Approximately 30% of
patients with MDS will develop to AML, especially those with
high-risk MDS. Poor clinical outcomes for this large and
Figure 5 DS/Cu selectively kills primary CD34+ AML patients cells while sparing normal hematopoietic progenitor cells. (a, b) Histogram of apoptosis percentage in primary
CD34+ AML cells (a) and normal CD34+ hematopoietic cells (b) after exposure to indicated concentrations of DS with 1.0 μM Cu for 24 h. Each symbol represents results for an
individual. Horizontal lines indicate the mean and SD for 14 AML patients and 8 healthy donors. (c, d) Histogram of colony-forming ability of primary CD34+ AML cells (c) and
normal CD34+ hematopoietic cells (d) after treatment with DS or DS/Cu for 18 h, compared with untreated control. Data were presented as mean± S.D. for three AML patients
and three healthy donors
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variable group of patients with sAML are associated with
greater incidence of chemo-resistance compared with those
with de novo AML. Interestingly, the marked ex vivo activity of
DS/Cu was observed in CD34+ cells isolated from patients
with sAML developed from MDS, without any significant
difference compared with those from patients with primary
AML, suggesting that patients with sAML might be also
susceptible to DS/Cu treatment. However, although the role of
Figure 6 DS/Cu suppresses growth of xenograft derived from leukemia stem-like cells. An xenograft model was established in NOD/SCID mice 4 weeks after inoculation of
CD34+/CD38− KG1a leukemia stem-like cells. Mice were randomly divided into DS/Cu group, Ara-C group and control group (eight per group). (a) Body weight changes of mice
received different treatments. (b) Histogram of proportion of blast cells in bone marrow evaluated microscopically after Wright staining. ***Po0.001. (c) Paraffin-embedded
sections of spleen and liver from mice were subjected to H&E staining and immunohistochemcal staining for hCD45 (×400). (d) Western blot analysis of spleen extracts from mice
using anti-Nrf2 antibody
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DS/Cu in patients with sAML remains to be defined in a larger
sample size of study, this finding provides initial evidence for
further exploration of DS/Cu in treatment of sAML evolved
from MDS.
It is well characterized that antitumor activity of most
chemotherapeutic agents is closely related to both generation
of ROS and disruption of redox homeostasis. As a conse-
quence, ROS induces collapse of mitochondria membrane
potential, thereby triggering a series of mitochondria-
associated events including apoptosis.37 In consistence with
these results, measurement of ROS level in leukemia stem-
like cells indicated that exposure to DS/Cu led to a marked
intracellular ROS burst, which functionally contribute to
DS/Cu-induced apoptosis, manifested by the abrogation of
cell death by the antioxidant NAC. Moreover, it has been
reported that ROS is a potent activator of JNK through
oxidative inactivation of endogenous JNK inhibitors, such as
JNK phosphatases and glutathione S-transferase π.19 The
results of the present study indicated that sustained activation
of the JNK pathway (e.g., phosphorylation of JNK and c-Jun)
was induced by DS/Cu in leukemia stem-like cells while
reversed by NAC that inhibited ROS production, supporting a
notion that ROS-activated JNK signal might be, at least in part,
responsible for DS/Cu-induced apoptosis.
It has widely accepted that in addition to induction of ROS,
the effect of anti-neoplastic agents is also associated with their
capability to inhibit activity of pro-survival transcription factors
and antioxidants. NF-κB is known to be aberrantly activated in
several types of tumor cells, including LSCs.38 Constitutive
activation of NF-κB may provide an unique opportunity to
preferentially target LSCs. Inhibition of NF-κB can also induce
intracellular ROS generation, leading to cell death.14 Con-
sistent with previously observations that DS is an effective
inhibitor of NF-κB,DS indeed downregulated p65 and inhibited
expression of the NF-κB downstream genes in leukemia stem-
like cells, whereas this event was markedly enhanced by
co-administration of Cu. Activation of the Nrf2 signaling
pathway represents a major mechanism for cellular defense
against oxidative stress. Its downstream targets are involved in
detoxification of harmful chemicals and removal of reactive
oxidants, consequently protecting cells from detrimental
stresses.28 Therefore, Nrf2 might be a potential target for
elimination of LSCs. In the present study, we observed that DS
and DS/Cu sharply reduced the protein level of Nrf2 both
in vitro and in vivo in leukemia stem-like cells, as well as
blocked the expression of Nrf2 target genes such as NQO1,
GSR, and HO-1. Downregulation of Nrf2 was partially
reversed by NAC, indicating that ROS increase might result
in decrease of Nrf2, thereby impairing its ability to protect cells
from ROS-mediated oxidative damage. Taken together, in
addition to activation of the ROS-JNK signaling cascade,
inactivation of NF-κB and Nrf2 might also contribute to anti-
leukemia activity of DS/Cu toward leukemia stem-like cells. It
is noteworthy that these pro-survival signaling pathways (e.g.,
NF-κB and Nrf2), as well as the stress-related ROS-JNK
pathway, are determinants for tumor cell survival versus death
in a variety of cancers.39–45 Thus, inactivation of NF-κB and
Nrf2 signals and/or activation of the ROS-JNK signaling
cascade might represent common mechanisms of action
underlying the antitumor activity of DS/Cu in diverse cancers,
including hematologic malignancies (e.g., myeloid and lym-
phoid leukemias) as we observed earlier.19,46
Collectively, the ability of DS in combination with Cu to
eliminate leukemia stem-like cells in vitro and in vivo indicate
that DS/Cu might represent a promising therapeutic repur-
posed agent to preferentially target LSCs, while sparing
normal hematopoietic progenitor cells. Mechanistically, the
anti-leukemia property of DS/Cu might attribute to induction of
apoptosis via ROS-mediated activation of the stress-related
JNK pathway and inactivation of the NF-κB and Nrf2 path-
ways. Therefore, the combination of DS and Cu warrants
further clinical investigation in treatment of refractory leuke-
mia, particularly targeting LSCs to reduce recurrence of this
disease.
Materials and Methods
Reagents. DS, copper chloride (CuCl2), and NAC were purchased from Sigma-
Aldrich (Dorset, UK) and dissolved in dimethyl sulfoxide or PBS, and freshly diluted
to required concentrations in subsequent experiments with culture medium
before use.
Primary patient samples. Mononuclear cells were isolated from peripheral
blood samples of healthy donors for hematopoietic stem cell transplantation (n= 8)
and bone marrow samples of newly diagnosed patients with AML (n= 17), which
were obtained with the informed consent for research purposes only at Department
of Hematology, Nanfang Hospital, Southern Medical University and Department of
Hematology, First Affiliated Hospital of Xiamen University. This study is approved by
the Ethics Review Board of Nanfang Hospital and First Affiliated Hospital of Xiamen
University, and performed in accordance with the Declaration of Helsinki. Clinical
characteristics are summarized in Table 1. Mononuclear cells were isolated by
density gradient centrifugation using Lymphoprep (BD, Franklin Lakes, NJ, USA)
and cultured in IMDM (HyClone, Thermo Scientific, Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS, Gibco, Life Technologies, Grand
Island, NY, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (1 × P/S) after
enrichment with a CD34 selection MACS kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer's protocol.
Cell culture and sorting. KG1α and Kasumi-1 cells were obtained from
Tianjing Institute of Hematology, Chinese Academy of Medical Sciences and
cultured in IMDM supplemented with 10% FBS and antibiotics (1 × P/S) in a 37 °C
incubator with 5% CO2. The CD34
+/CD38− population was obtained by staining with
CD34-allophycocyanin (CD34–APC; Becton Dickinson Biosciences, Oxford, UK)
and CD38-fluorescein isothiocyanate (CD38–FITC; Becton Dickinson Biosciences)
and then subjected to sorting using FACS Aria II.
Cell viability assay. Cell viability was determined by MTT assay. CD34+
/CD38− KG1α cells and CD34+/CD38− Kasumi-1 cells were inoculated in a 96-well
plate at a density of 2 × 104/well in 100 μl growth medium and then treated with
designated doses of DS with or without Cu (1 μM) for 24 h. Then, a final
concentration of 5 mg/ml MTT in PBS was added to each well and incubated for
4 h. Viable cells were detected by measuring absorbance at 490 nm using an
Multisckan MCC340 microplate reader (Labsystem, Helsinki, Finland). All
experiments were conducted in triplicate. IC50 value (half maximal inhibitory
concentration) was calculated by GraphPad Prism 5.
Flow cytometric analysis of apoptosis. Annexin V-FITC/PI staining was
performed according to the manufacturer’s instruction to detect the apoptotic cells.
In brief, CD34+/CD38− KG1α cells, CD34+CD38− Kasumi-1 cells, primary CD34+
AML cells, and normal CD34+ hematopoietic cells were treated with escalating
concentration of DS with or without Cu (1 μM) for 24 h. Cells were harvested after
washing twice with iced PBS and then stained with Annexin V-FITC/PI for 20 min at
4 °C in the dark. The percentage of apoptotic cells was determined by FACS C6
(BD, Oxford, UK). At least 30 000 gated events were acquired from each sample.
Measurement of intracellular ROS. Cells were exposed to DS alone or in
combination with Cu (1 μM) for indicated time points (6, 12, 18, 24 h), then
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supernatants were removed and cells were labeled with 2′,7′-dichlorofluorescin-
diacetate (DCFH-DA, Invitrogen, Paisley, UK) at 37 °C for 30 min. Cells were
washed twice with PBS and maintained in 1 ml serum-free medium. Cellular ROS
level was analyzed using a FACS Calibur machine (Becton Dickinson, San Jose,
CA, USA). Each sample was measured at least in triplicate.
Colony formation assay. The colony-forming capacity of CD34+/CD38−
KG1α cells and CD34+ primary AML cells was measured using methylcellulose
medium (Methocult H4434, Stem Cell Technologies, Vancouver, BC, Canada)
according to the manufacturer's instructions. In brief, cells were cultured in six-well
plates with Methocult H4434 at a density of 500 cells/well after treated with DS
alone or in combination with Cu (1 μM) for 18 h. After incubation at 37 °C for 10–
14 days, CFU consisting of 40 or more cells were counted under microscope.
Western blot analysis. After cell lysis, 50 μg/lane of proteins from each
sample was resolved in 10% SDS-polyacrylamide gel electrophoresis and then
transferred to PVDF membrane (Millipore, Billerica, MA, USA). After blocking with
5% non-fat milk in Tris-buffered saline-Tween 20 (TBS-T) for 2 h, the membrane was
incubated overnight at 4 °C with the primary antibody, followed by appropriate
secondary HRP-conjugated antibody (1:10 000, Cell Signaling Technology, Herts,
UK) in TBS-T for 2 h at room temperature. The proteins were visualized on X-ray
film using an ECL Western blotting detection kit (Cell Signaling Technology).
GAPDH and PCNA were probed as loading controls.
Quantitative real-time PCR (qPCR). Cells were lysed with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) and total RNA from each sample was extracted
with chloroform and isopropyl alcohol. cDNA was synthesize using a reverse
transcription reagent kit (TaKaRa, Dalian, China) according to the manufacturer’s
instructions. Quantitative real-time PCR was carried out by a SYBR Prime Script RT-
PCR kit (Takara) using the following primers (synthesized by Takara). The relative
levels of mRNA expression were determined by the 2−ΔΔCt method.
NQO1: 5′-GTGGCAGTGGCTCCATGTACTC-3′(forward),
5′-GAGTGTGCCCAATGCTATATGTCAG-3′ (reverse);
GSR: 5′-CCTGATCGCCACAGGTGGTA-3′ (forward),
5′- CTGCCATCTCCACAGCAATGTAA-3′ (reverse);
HO-1: 5′- TTGCCAGTGCCACCAAGTTC-3′ (forward),
5′- TCAGCAGCTCCTGCAACTCC-3′ (reverse);
GAPDH: 5′-TCTCTGCTCCTCCTGTTC-3′(forward),
5′-CTCCGACCTTCADCTTCC-3′ (reverse);
Animal study. NOD/SCID mice (6–8 weeks old, non-fertile, female, and
18–20 g each) were purchased from the Experimental Center of Southern Medical
University and bred in a pathogen-free environment and supplied with sterile food
and water. All animal study procedures were approved by Nanfang Hospital of
Southern Medical University Animal Care and Use Committee. After receiving 1 Gy
of sublethal irradiation, mice were intravenously injected with 2 × 106 CD34+
/CD38− KG1α cells resuspended in 200 μl PBS and then monitored weekly for
signs of weight loss or lethargy, and leukocytes in peripheral blood. After
percentage of hCD45+ in peripheral blood reached 1%, mice were randomly
assigned to three groups (n= 8 per group). DS/Cu treatment was given by gavage
as follows: 3 mg/20 g/day for DS per morning and 0.03 mg/20 g/day for Cu per
afternoon for 2 weeks. Ara-C treatment was given as follows for comparison: 40 mg/
20 g/day for 2 days before killing. Mice of the control group received vehicle
(i.e., PBS, 0.2 ml/20 g/d for 2 weeks). Mice were killed after 2 weeks and invasion of
leukemia cells was evaluated by H&E staining for pathological changes and
immunohistochemical staining for hCD45.
Immunohistochemical staining. Paraffin-embedded liver and spleen
tissue from mice were sectioned and deparaffinized with xylene. Then slides were
subjected to rehydration with different concentrations of alcohol. For antigen
retrieval, slides were immersed in boiling citrate buffer for 30 min and then incubated
with primary antibody against hCD45 overnight at 4 °C after blocking with 3% BSA
solution at room temperature for 30 min. After washing, HRP Polymer Conjugate
Reagent (SuperPicture Polymer Detection kit) and DAB Chromogen were added.
Mayer’s Hematoxylin solution was used for counterstaining. Finally, slides were
dehydrated, air-dried and mounted. For hematoxylin and eosin staining (H&E stain)
slides were immersed in a coplin jar containing Mayer’s hematoxylin solution,
washed with distilled water and then counterstained with eosin Y solution.
Statistical analysis. All statistical analyses were performed using the SPSS
13.0 statistical software package. Comparisons between two groups were analyzed
using the two-tailed Student’s t-test. Comparisons among multiple groups were
performed using the one-way ANOVA, followed by LSD test if the variance was
homogenous, whereas if not, Dunnett’s T3 was employed.*Po0.05 was considered
as statistical significance.
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